Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inès Vergnolle

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Blood Advances|September 27, 2021
CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndromeInès Vergnolle, Claudia Douat-Beyries, Serge Boulinguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid LeukemiaAlban Canali, Inès Vergnolle, Sarah Bertoli, et al.
Leukemia|April 4, 2024
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasmsCharles Dussiau, Thibault Comont, Camille Knosp, et al.
Blood Cancer Journal|August 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemiaFrançois Vergez, Laetitia Largeaud, Sarah Bertoli, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Blood Advances|September 27, 2021
CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndromeInès Vergnolle, Claudia Douat-Beyries, Serge Boulinguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid LeukemiaAlban Canali, Inès Vergnolle, Sarah Bertoli, et al.
Leukemia|April 4, 2024
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasmsCharles Dussiau, Thibault Comont, Camille Knosp, et al.
Blood Cancer Journal|August 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemiaFrançois Vergez, Laetitia Largeaud, Sarah Bertoli, et al.
Pageof 2